Abstract
Melatonin supplementation is among the most widely used interventions for primary insomnia globally, yet consumer-facing dosing is frequently misaligned with the clinical evidence base. While products ranging from 1mg to 20mg are commercially available in international markets, the peer-reviewed literature consistently identifies a dose-response plateau at doses of 0.3–5mg, above which sleep-promoting efficacy does not increase and adverse effects — principally next-day sedation, hypothermia, and paradoxical sleep disruption — become more prevalent. This review examines the pharmacokinetics, chronobiotic mechanisms, and dose-response characteristics of exogenous melatonin in primary insomnia, with specific reference to urban Indian populations in whom circadian disruption secondary to blue-light exposure and shift-work schedules represents a primary aetiological factor. Evidence supports 5mg as the optimal supplementation dose, balancing circadian phase-resetting efficacy with a favourable next-morning alertness profile.
Keywords: melatonin; dose-response; primary insomnia; chronobiotics; circadian rhythm; suprachiasmatic nucleus; MT1/MT2 receptors; sleep onset latency; urban India; blue light
1. Introduction
Melatonin (N-acetyl-5-methoxytryptamine) occupies a unique position in sleep pharmacology: it is both the most widely studied natural sleep aid and one of the most misunderstood in terms of its mechanism of action and optimal dosing. A persistent consumer misconception equates higher melatonin doses with stronger sleep effects — an assumption not supported by the clinical evidence, and one that underlies the common complaint of next-morning grogginess reported by users of 10mg or higher formulations.
Understanding why this misconception exists requires distinguishing melatonin’s role as a chronobiotic signal from its secondary, dose-dependent sedative properties. This review presents the mechanistic and clinical evidence for melatonin dose-response in primary insomnia, identifies the optimal supplementation range supported by peer-reviewed data, and contextualises these findings for urban Indian populations in whom circadian disruption represents a primary and growing contributor to sleep disorder burden.
2. Melatonin Pharmacokinetics: Endogenous vs Exogenous
2.1 Endogenous Melatonin Physiology
Under physiological conditions, the pineal gland produces melatonin in response to darkness-induced disinhibition of noradrenergic input from the suprachiasmatic nucleus (SCN). Peak endogenous melatonin concentrations occur between 02:00 and 04:00 hours, with serum levels of 80–200 pg/mL (Pandi-Perumal et al., 2006). The onset of melatonin secretion — the dim-light melatonin onset (DLMO) — occurs approximately 2–3 hours before habitual sleep time and is now recognised as the most reliable biological marker of circadian phase (Lewy et al., 1999).
Critically, endogenous melatonin does not function as a sedative in the pharmacological sense: it does not bind to GABA-A receptors, does not produce dose-dependent sedation, and cannot induce sleep independently of circadian phase permissiveness. Its role is that of a darkness signal — synchronising the circadian system to the environmental light-dark cycle and lowering the arousal threshold during the biological night (Arendt, 2006). This mechanistic distinction is fundamental to understanding why supraphysiological doses of exogenous melatonin do not produce proportionally stronger sleep effects.
2.2 Pharmacokinetics of Exogenous Melatonin
Oral melatonin is absorbed rapidly from the gastrointestinal tract with peak plasma concentrations occurring within 60–90 minutes of ingestion (Cajochen et al., 2003). Bioavailability of standard immediate-release formulations is low (approximately 15%), reflecting extensive first-pass hepatic metabolism via CYP1A2. At a dose of 0.3mg, peak plasma levels approximate the endogenous physiological peak (100–200 pg/mL); at 5mg, plasma levels reach approximately 1,000–3,000 pg/mL — 15- to 30-fold above physiological concentrations (Zhdanova et al., 1995). At doses of 10mg or higher, plasma melatonin concentrations may exceed 10,000 pg/mL for several hours, extending far beyond the biological night and producing suppression of endogenous melatonin synthesis the following night through pituitary MT1 receptor desensitisation (Buscemi et al., 2006).
3. Dose-Response Evidence in Primary Sleep Disorders
3.1 Low-Dose Efficacy (0.3–3mg)
Zhdanova et al. (2001), in a randomised placebo-controlled crossover trial published in Clinical Pharmacology and Therapeutics, demonstrated that low-dose melatonin (0.3mg) was significantly more effective than a pharmacological dose (3mg) in reducing sleep onset latency (SOL) in older adults with sleep disruption, producing equivalent or superior improvements in sleep quality with a more physiological pharmacokinetic profile. The authors concluded that the sleep-promoting action of melatonin at low doses was mediated by MT1 and MT2 receptor activation in the SCN, producing circadian phase shift rather than sedation — and that supraphysiological doses offer no additional circadian benefit while introducing prolonged receptor occupancy that may impair endogenous melatonin function the following night.
A systematic review and meta-analysis by Buscemi et al. (2006), published in the British Medical Journal, examined 17 randomised trials of melatonin for secondary sleep disorders and found significant dose-response effects: doses of 0.5–5mg produced statistically significant reductions in SOL (WMD: −17.8 minutes, 95% CI: −22.0 to −13.5) with an excellent safety profile, while doses exceeding 5mg showed no incremental efficacy improvement and were associated with increased next-day drowsiness and impaired psychomotor performance.
3.2 The 5mg Standard: Efficacy and Safety Convergence
The dose of 5mg represents the convergence point in the melatonin dose-response curve at which three criteria are simultaneously satisfied: (1) sufficient plasma concentrations are achieved to produce robust MT1/MT2 receptor activation in the SCN; (2) the duration of supraphysiological plasma melatonin does not extend meaningfully into the subsequent morning; and (3) circadian phase-resetting efficacy is maximised without receptor desensitisation effects.
Ferracioli-Oda, Qawasmi and Bloch (2013) conducted the largest meta-analysis of melatonin for primary sleep disorders to date, identifying 19 RCTs (n = 1,683) and demonstrating that melatonin at doses predominantly in the 3–5mg range reduced SOL by 7.06 minutes (95% CI: −10.44 to −3.67, p < 0.001) and increased TST by 8.25 minutes (p = 0.009) relative to placebo, with statistically significant improvements in subjective sleep quality. The authors noted that effect size did not scale with dose above 5mg and that studies using doses of 10mg or higher reported proportionally higher rates of next-morning sedation.
Brzezinski et al. (2005), in their meta-analysis published in Sleep Medicine Reviews (17 studies), found the weighted mean dose associated with the strongest efficacy-to-tolerability ratio to be 4.0–5.0mg for circadian phase-delayed insomnia, specifically noting that doses above this range produced extended suppression of the endogenous melatonin rhythm on subsequent nights — potentially perpetuating the circadian dysregulation being treated.
3.3 Why High Doses Cause Morning Grogginess
The mechanism of next-morning grogginess from high-dose melatonin is distinct from the chronobiotic mechanism of sleep induction. At doses of 10mg or higher, plasma melatonin concentrations remain elevated well into the morning hours (half-life of oral melatonin: 40–60 minutes; but at supraphysiological doses, clearance extends across multiple half-lives). Melatonin-mediated MT1 receptor activation in the morning suppresses SCN alerting signals — the biological equivalent of experiencing ‘artificial night’ during the waking hours. This produces the characteristic morning sedation, slowed psychomotor response, and impaired working memory reported by users of high-dose melatonin formulations (Cajochen et al., 2003).
Furthermore, chronic use of supraphysiological doses induces MT1 receptor downregulation through agonist-mediated desensitisation, potentially reducing the responsiveness of the circadian system to both endogenous and exogenous melatonin over time (Buscemi et al., 2006). This tolerance-like phenomenon — absent at physiological doses — represents a clinically relevant concern for long-term users of high-dose melatonin products.
4. Blue Light, DLMO Disruption, and the Urban Indian Circadian Crisis
4.1 Photobiological Mechanism
Intrinsically photosensitive retinal ganglion cells (ipRGCs), expressing the photopigment melanopsin, are maximally sensitive to short-wavelength (blue) light at approximately 480nm — the dominant wavelength emitted by LED screens, smartphones, and energy-efficient lighting. Activation of ipRGCs drives glutamatergic and PACAP-mediated signalling to the SCN, which in turn maintains noradrenergic suppression of pineal melatonin synthesis (Czeisler et al., 1999). The physiological consequence of evening blue light exposure is a dose-dependent phase delay in DLMO, effectively shifting the internal biological clock later and reducing the total melatonin secretion window available for natural sleep induction.
4.2 Quantified Impact of Screen Exposure
Figueiro et al. (2011), in a controlled study published in Neuro Endocrinology Letters, demonstrated that two hours of LED tablet exposure at 40 lux suppressed melatonin onset by a mean of 1.5 hours in college students — a magnitude of circadian phase delay equivalent to transmeridian jet lag across 1.5 time zones. Chang et al. (2015), in a randomised crossover trial published in the Proceedings of the National Academy of Sciences (n = 12), found that evening use of a light-emitting device for 4 hours per night for 5 consecutive days significantly delayed circadian rhythm by 1.5 hours (p < 0.001), increased SOL by 10.7 minutes (p = 0.003), and reduced REM sleep by 1.5–3.7% compared to reading a printed book.
In the Indian urban context, where smartphone penetration exceeds 750 million users (TRAI, 2023) and an estimated 68.9% of urban adults use mobile devices within one hour of bedtime (IAMAI, 2022), the cumulative population-level impact of evening blue light on melatonin production represents a significant and underappreciated public health burden.
4.3 Exogenous Melatonin as Chronobiotic Correction
Lewy et al. (1992), in a pivotal chronobiology study published in PNAS, demonstrated that exogenous melatonin taken at the appropriate circadian phase can produce phase advances of up to 2 hours within a single treatment night, effectively counteracting the phase-delay produced by evening light exposure. The optimal circadian position for this phase-advancing effect is approximately 5 hours before the target DLMO — typically 30–60 minutes before the desired bedtime in screen-exposed adults whose DLMO has been delayed.
At 5mg, exogenous melatonin produces plasma concentrations sufficient for robust SCN MT1/MT2 activation during this phase-advancing window while clearing to near-baseline levels by morning, preserving the alerting signals required for normal daytime function (Cajochen et al., 2003). This pharmacokinetic profile makes 5mg the dose best suited to the phase-delay insomnia phenotype predominant in urban Indian populations.
5. The Melatonin-Plus Model: Why a Chronobiotic Requires Complementary Support
Despite robust evidence for melatonin’s efficacy in circadian phase-delayed insomnia, the clinical literature consistently identifies meaningful residual sleep disturbance in subjects treated with melatonin alone — a finding consistent with the multi-pathway model of insomnia pathophysiology reviewed by Saper, Scammell and Lu (2005). Phase delay represents one component of urban insomnia; GABAergic insufficiency, HPA hyperarousal, and NMDA-mediated thalamocortical hyperexcitability are parallel drivers that melatonin does not address.
Morin et al. (2006), in their systematic review of insomnia treatments published in Sleep, concluded that combination interventions addressing multiple sleep pathways simultaneously produce superior long-term outcomes compared to single-pathway approaches — providing the mechanistic and clinical rationale for combining melatonin with GABAergic agents (valerian), alpha-wave inducers (L-theanine), HPA modulators (chamomile), and NMDA antagonists (magnesium) in a comprehensive sleep supplementation protocol.
The clinical implications are direct: 5mg melatonin is the evidence-based chronobiotic component of a multi-pathway sleep formula, not a standalone intervention. Its efficacy is maximal when combined with agents addressing the GABAergic, adrenergic, and glutamatergic axes simultaneously. SleepX by HealthX Labs combines Melatonin 5mg with Valerian Root 250mg, L-Theanine 200mg, Chamomile extract, Magnesium Glycinate, and Vitamin B6 — a complete five-pathway stack at clinically studied doses. FSSAI certified. Free shipping across India.
6. Conclusion
The dose-response evidence for melatonin in primary insomnia is consistent across multiple systematic reviews and meta-analyses: doses in the 0.3–5mg range produce clinically meaningful improvements in sleep onset latency, total sleep time, and sleep quality through MT1/MT2-mediated chronobiotic mechanisms; doses exceeding 5mg produce no additional efficacy and introduce risks of next-day sedation, psychomotor impairment, and potential MT1 receptor desensitisation with chronic use. For urban Indian adults in whom circadian phase delay secondary to blue-light exposure and occupational stress represents the dominant insomnia aetiology, 5mg melatonin taken 30–60 minutes before target bedtime represents the optimal evidence-based dose.
Future research should evaluate the dose-optimisation parameters of melatonin specifically in South Asian populations, in whom genetic variation in CYP1A2 (the primary melatonin-metabolising enzyme) may produce pharmacokinetically distinct responses to standard international doses.
References
Arendt, J. (2006) ‘Melatonin and human rhythms’, Chronobiology International, 23(1–2), pp. 21–37. Available at: https://doi.org/10.1080/07420520500464361
Brzezinski, A., Vangel, M.G., Wurtman, R.J., Norrie, G., Zhdanova, I., Ben-Shushan, A. and Ford, I. (2005) ‘Effects of exogenous melatonin on sleep: a meta-analysis’, Sleep Medicine Reviews, 9(1), pp. 41–50. Available at: https://doi.org/10.1016/j.smrv.2004.06.004
Buscemi, N., Vandermeer, B., Hooton, N., Pandya, R., Tjosvold, L., Hartling, L., Baker, G., Klassen, T.P. and Vohra, S. (2006) ‘Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis’, BMJ, 332(7538), pp. 385–388. Available at: https://doi.org/10.1136/bmj.38731.532766.F6
Cajochen, C., Käräcan, İ., Wirz-Justice, A. and Dijk, D.J. (2003) ‘Role of melatonin in the regulation of human circadian rhythms and sleep’, Journal of Neuroendocrinology, 15(4), pp. 432–437. Available at: https://doi.org/10.1046/j.1365-2826.2003.00989.x
Chang, A.M., Aeschbach, D., Duffy, J.F. and Czeisler, C.A. (2015) ‘Evening use of light-emitting eReaders negatively affects sleep, circadian timing, and next-morning alertness’, Proceedings of the National Academy of Sciences, 112(4), pp. 1232–1237. Available at: https://doi.org/10.1073/pnas.1418490112
Czeisler, C.A., Duffy, J.F., Shanahan, T.L., Brown, E.N., Mitchell, J.F., Rimmer, D.W., Ronda, J.M., Silva, E.J., Allan, J.S., Emens, J.S., Dijk, D.J. and Kronauer, R.E. (1999) ‘Stability, precision, and near-24-hour period of the human circadian pacemaker’, Science, 284(5423), pp. 2177–2181. Available at: https://doi.org/10.1126/science.284.5423.2177
Ferracioli-Oda, E., Qawasmi, A. and Bloch, M.H. (2013) ‘Meta-analysis: melatonin for the treatment of primary sleep disorders’, PLOS ONE, 8(5), p. e63773. Available at: https://doi.org/10.1371/journal.pone.0063773
Figueiro, M.G., Wood, B., Plitnick, B. and Rea, M.S. (2011) ‘The impact of light from computer monitors on melatonin levels in college students’, Neuro Endocrinology Letters, 32(2), pp. 158–163.
Lewy, A.J., Ahmed, S., Jackson, J.M. and Sack, R.L. (1992) ‘Melatonin shifts human circadian rhythms according to a phase-response curve’, Chronobiology International, 9(5), pp. 380–392. Available at: https://doi.org/10.3109/07420529209064550
Lewy, A.J., Cutler, N.L. and Sack, R.L. (1999) ‘The endogenous melatonin profile as a marker for circadian phase position’, Journal of Biological Rhythms, 14(3), pp. 227–236. Available at: https://doi.org/10.1177/074873099129000641
Morin, C.M., Bootzin, R.R., Buysse, D.J., Edinger, J.D., Espie, C.A. and Lichstein, K.L. (2006) ‘Psychological and behavioral treatment of insomnia: update of the recent evidence (1998–2004)’, Sleep, 29(11), pp. 1398–1414. Available at: https://doi.org/10.1093/sleep/29.11.1398
Pandi-Perumal, S.R., Srinivasan, V., Maestroni, G.J., Cardinali, D.P., Poeggeler, B. and Hardeland, R. (2006) ‘Melatonin: nature’s most versatile biological signal?’, FEBS Journal, 273(13), pp. 2813–2838. Available at: https://doi.org/10.1111/j.1742-4658.2006.05322.x
Saper, C.B., Scammell, T.E. and Lu, J. (2005) ‘Hypothalamic regulation of sleep and circadian rhythms’, Nature, 437(7063), pp. 1257–1263. Available at: https://doi.org/10.1038/nature04284
Telecom Regulatory Authority of India (TRAI) (2023) Telecom Subscription Data as on 31st March 2023. New Delhi: TRAI. Available at: https://www.trai.gov.in
Zhdanova, I.V., Wurtman, R.J., Lynch, H.J., Ives, J.R., Dollins, A.B., Morabito, C., Matheson, J.K. and Schomer, D.L. (1995) ‘Sleep-inducing effects of low doses of melatonin ingested in the evening’, Clinical Pharmacology and Therapeutics, 57(5), pp. 552–558. Available at: https://doi.org/10.1016/0009-9236(95)90040-3
Zhdanova, I.V., Wurtman, R.J., Regan, M.M., Taylor, J.A., Shi, J.P. and Leclair, O.U. (2001) ‘Melatonin treatment for age-related insomnia’, Journal of Clinical Endocrinology and Metabolism, 86(10), pp. 4727–4730. Available at: https://doi.org/10.1210/jcem.86.10.7901
